Roche

bluebird bio Responds to Marketing Campaign Lawsuit with Countersuit
BioSpace
Wed, 07/7/21 - 10:25 pm
pharma marketing
Bluebird Bio
Spark Therapeutics
Roche
WHO signs off on IL-6 drugs to treat severe Covid-19 cases, reigniting pricing debate
Endpoints
Wed, 07/7/21 - 10:55 am
WHO
COVID-19
IL-6
Sanofi
Kevzara
Roche
Actemra
Roche to seek early FDA approval for Alzheimer’s therapy: Jefferies
Seeking Alpha
Thu, 07/1/21 - 10:45 am
Roche
FDA
Alzheimer's disease
gantenerumab
Roche confirms it could cut 300 to 400 product development jobs
Fierce Biotech
Thu, 07/1/21 - 10:42 am
Roche
layoffs
product development
Switzerland
Key third-quarter readouts for big pharma
EP Vantage
Tue, 06/29/21 - 10:59 am
clinical trials
Pfizer
Roche
idanacogene elaparvovec
Alexion
AstraZeneca
Ultomiris
AbbVie
Rinvoq
Novartis
sabatolimab
Roche Scores Wins in AMD & COVID-19 in Big Week
BioSpace
Sun, 06/27/21 - 12:02 am
Roche
Genentech
COVID-19
wet age-related macular degeneration
FDA allows emergency use of Roche’s Actemra for Covid-19
Pharmaceutical Business Review
Fri, 06/25/21 - 11:06 am
Roche
Actemra
COVID-19
Emergency Use Authorization
Roche's Genentech launches new alliance aimed at achieving greater diversity in cancer trials
Fierce Biotech
Thu, 06/24/21 - 11:02 am
Roche
Genentech
clinical trials
clinical trial diversity
cancer
Advancing Inclusive Research Site Alliance
Roche eyes October decision by FDA for wet AMD implant
Pharmaforum
Thu, 06/24/21 - 11:00 am
Roche
FDA
wet age-related macular degeneration
ranibizumab
Arcus declares cryptic interim win for closely watched anti-TIGIT drug, but you'll have to wait for the data
Endpoints
Wed, 06/23/21 - 10:32 pm
Arcus Biosciences
anti-TIGIT
Roche
Roche's Alzheimer's antibody lowers biomarkers in inherited form of disease, though impact on symptoms is unclear
Fierce Biotech
Mon, 06/21/21 - 11:08 am
Roche
gantenerumab
Alzheimer's disease
clinical trials
biomarkers
Novartis touts latest Zolgensma data as SMA competition against Biogen, Roche heats up
Fierce Pharma
Sun, 06/20/21 - 10:21 pm
Novartis
SMA
spinal muscular atrophy
Zolgensma
Roche
Evresdi
Eli Lilly, Roche's Alzheimer's prospects, including flops, boosted in light of FDA's Aduhelm approval: analysts
Fierce Biotech
Fri, 06/11/21 - 12:10 pm
Eli Lilly
Roche
Biogen
Alzheimer's disease
FDA
beta-amyloid plaque
Roche, Pfizer and Novartis earn top marks from cancer patient groups during pandemic: survey
Fierce Pharma
Mon, 06/7/21 - 08:29 pm
cancer
patients
COVID-19
pandemic
Roche
Pfizer
Novartis
Analysts throw cold water on Exelixis and Roche's prostate cancer data, putting the pair a further step behind Novartis
Endpoints
Tue, 05/25/21 - 11:08 am
Exelixis
Cabometyx
Roche
Tecentriq
prostate cancer
Roche's Spark sues gene therapy rival bluebird for using 'spark' in its marketing campaigns
Fierce Pharma
Thu, 05/20/21 - 11:15 am
Roche
Spark Therapeutics
Bluebird Bio
gene therapy
trademark
Roche CEO Schwan joins chorus of pharma execs blasting COVID patent waiver
Fierce Pharma
Fri, 05/14/21 - 10:54 am
Roche
Severin Schwan
Pharma CEOs
COVID-19
vaccines
intellectual property
Validation for a drug class, and for Sanofi
EP Vantage
Wed, 05/12/21 - 10:44 am
Sanofi
Serds
breast cancer
Amcenestrant
Radius Health
Elacestrant
Roche
Giredestrant
AstraZeneca
Camizestrant
Merck, Roche and Bristol Myers nab 4 of 6 positive ODAC votes for ‘dangling’ accelerated approvals
Endpoints
Thu, 04/29/21 - 10:55 pm
Merck
Roche
Bristol Myers Squibb
FDA
ODAC
accelerated approvals
Keytruda
Opdivo
Tecentriq
ODAC votes to keep Keytruda and Tecentriq accelerated approvals in bladder cancer
Endpoints
Wed, 04/28/21 - 10:12 pm
FDA
ODAC
accelerated approvals
Merck
Keytruda
Roche
Tecentriq

Pages